KV Pharma, ex-chief wrestle over roots of 2008 crisis

How to explain KV Pharmaceuticals' sudden skid in 2008? The company has one version, and ex-CEO Mark Hermelin has another--and that's the gist of the ongoing court fight. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.